



August 6, 2026

To,
BSE Limited
P J Towers, Dalal Street,
Fort, Mumbai- 400 001.

To,
National Stock Exchange of India Ltd
Exchange Plaza, Bandra Kurla Complex,
Bandra(E), Mumbai- 400 051.

Scrip Code : 524518

Scrip Code : KREBSBIO

Dear Sir / Madam,

Sub: Outcome of Board Meeting – Unaudited Financial Results for the 1st quarter ended 30th June 2026.

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that the Board of Directors of the Company at its meeting held today approved and taken on record the following:

1. Unaudited Financial Results of the Company for the 1st quarter ended June 30, 2026.
2. Limited Review Report by the Auditors on the Unaudited Financial Results for the 1st quarter ended June 30, 2026.

The Meeting of the Board of Directors commenced at 11:30 am and concluded at 01:30 p.m.

The above is for your information and record.

Thanking you,

Yours Faithfully,
For Krebs Biochemicals and Industries Limited

Rakesh Ravindra
Kalbate

Rakesh R Kalbate
Company Secretary & Compliance Officer

Encl.: a/a.

KREBS BIOCHEMICALS & INDUSTRIES LIMITED					
CIN:L24110AP1991PLC103912					
Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031					
STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026					
(Rs. in lacs)					
Sr.No	Particulars	Quarter Ended			Year Ended
		30.06.2026 (Un Audited)	31.03.2026 (Audited) *	30.06.2025 (Un Audited)	31.03.2026 (Audited)
1	Revenue from Operations	698.35	680.91	548.09	2,373.16
2	Other Income	15.65	200.36	1.17	202.63
3	Total Income (1+2)	714.00	881.27	549.26	2,575.79
4	Expenses				
	a) Cost of Material Consumed	(0.03)	0.79	3.93	5.05
	b)Purchase of Stock- in -Trade	50.69	-	-	-
	c) Changes in Inventories of Finished goods, Work-In-Progress	(9.54)	9.02	24.99	34.01
	d) Employee Benefits Expenses	277.92	225.46	275.11	1,038.80
	e) Finance Costs	188.05	191.00	165.01	708.59
	f) Depreciation and Amortisation Expense	158.78	156.57	159.87	642.33
	g) Other Expenses	296.61	532.39	452.78	1,840.32
	Total Expenses (4)	962.48	1,115.23	1,081.69	4,269.10
5	Profit / (Loss) before exceptional items and tax (3-4)	(248.48)	(233.96)	(532.43)	(1,693.31)
6	Exceptional Items	-	-	-	-
7	Profit / (Loss) before Tax (5 + 6)	(248.48)	(233.96)	(532.43)	(1,693.31)
8	Tax Expense				
	a) Current Tax	-	-	-	-
	b) Tax payment of earlier years	-	-	-	-
	c) Deferred Tax	-	-	-	-
9	Profit / (Loss) for the period from Continuing Operations (7+8)	(248.48)	(233.96)	(532.43)	(1,693.31)
10	Other Comprehensive Income				
i	Items that will not be reclassified to profit or Loss	-	41.72	-	41.72
ii	Income tax relating to items that will not be reclassified to profit or Loss	-	-	-	-
iii	Items that will be reclassified to profit or Loss	-	-	-	-
iv	Income tax relating to items that will be reclassified to profit or Loss	-	-	-	-
	Other Comprehensive Income (Net of Tax)	-	41.72	-	41.72
11	Total Comprehensive Income for the period(9+10)	(248.48)	(192.24)	(532.43)	(1,651.59)
12	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	2,156.06	2,156.06	2,156.06	2,156.06
13	Other Equity	-	-	-	(19,536.61)
14	Earning Per Share (of Rs.10/- each) (not Annualised)				
	a) Basic	(1.15)	(1.09)	(2.47)	(7.85)
	b) Diluted	(1.15)	(1.09)	(2.47)	(7.85)
15	Net Worth (including Retained Earnings)	-	-	-	(16,275.47)
Notes:					
1	The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on Aug 06, 2026.				
2	The Statutory Auditors have carried out audit of the aforesaid results and have issued their "Unmodified Report" thereon.				
3	The above financial results are prepared in accordance with the Indian Accounting Standards(IND AS) as prescribed under Section 133 of the companies Act,2013 and are in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations,2015 (as Amended).				
4	The Company is operating in one segment only hence no segment results have been disclosed.				
5	As at June 30,2026 the Company does not have any Subsidiary/Associate/Joint venture company(ies).				
6	The Operations of the Company's Vizag manufacturing unit continued to remain closed pursuant to order dated 7th February 2025 passed by the Andhra Pradesh Pollution Control Board. The company has taken various steps in this matter and is in constant dialogue with the Pollution Control Board for revocation of the closer order.				
7	Figures of the previous period have been regrouped to confirm to the figures of the current period's classification wherever necessary.				
8	The Board of Directors have approved the amalgamation of Krebs Biochemicals & Industries Limited with Ipca Laboratories Limited at their meeting held on June 26, 2026, subject to necessary consents/ approvals. The appointed date for this scheme of amalgamation is April 1, 2026.				
9	* The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full financial year 2025-26 and the published year to date reviewed figures Upto December 31, 2025.				
Place: Mumbai		 Marish Kumar Jain Managing Director/ CEO DIN : 06477976			
Date: Aug 06,2026					



Independent Auditor's Review Report on the Quarterly Unaudited standalone Financial Results of the company pursuant to the regulation 33 and 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, as amended

Review Report to

The Board of Directors,

M/s. KREBS BIOCHEMICALS AND INDUSTRIES LIMITED

- a) We have reviewed the accompanying statement of unaudited standalone financial results of M/s. KREBS BIOCHEMICALS AND INDUSTRIES LIMITED ("the company") for the quarter ended 30th June, 2026 (the "Statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended (the "Listing Regulations")
- b) The statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
- c) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- d) Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ('IND AS') specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of listing regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Bhavani & Co.

Chartered Accountants

Firm Registration No: 012139S



CA S Kavitha Padmini

Partner

Membership no: 229966

UDIN: 2622996650W4YN5707

Place: Hyderabad

Date: 06/08/2026